LOXL3 and melanoma: Our study, using two experimental methods, immunofluorescence and qPCR analysis, reports on the aberrant LOXL3, SNAI1, and NES expression and their co-expression in dysplastic nevi, melanoma in situ, and BRAF+ and BRAF– melanoma.